Paclitaxel micelles for advanced head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new form of chemotherapy called paclitaxel polymeric micelles for people with head and neck cancer that has come back or spread. It is for patients who have already tried one line of treatment and may benefit from a different option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have head and neck cancer that has returned or spread to other parts of the body, and you have already had one type of treatment (chemo, targeted therapy, or immunotherapy) that stopped working or wasn't helping anymore.
- You are in fairly good health (able to do daily activities with little or no help) and expected to live at least 3 more months.
- You have at least one tumor that can be measured on a scan.
- Your blood counts, liver, and kidney function are within certain limits (your doctor will check this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests an approach that alternates treatments for advanced lung cancer or recurrent/metastatic head and neck squamous cell cancer. It may help by improving how well the cancer responds while managing side effects differently than standard back-to-back therapy.
This trial tests a combination of three drugs (tirelizumab, carboplatin, and a special form of paclitaxel) given before surgery to treat advanced head and neck cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a combination of paclitaxel polymer micelles with other drugs for people with advanced bone or soft tissue sarcoma that has worsened after first-line chemotherapy. The goal is to see if this new formulation can help shrink tumors or slow their growth.
This study tests a new chemotherapy combination (paclitaxel polymeric micelles with HP and adebelimab) versus standard chemotherapy for advanced breast cancer that tests positive for HER2. The goal is to see if this approach helps patients live longer and controls cancer better.
This trial tests a combination of low-dose oral paclitaxel (a chemotherapy pill taken regularly) plus immunotherapy to treat advanced breast cancer that doesn't have high levels of HER2 protein. The goal is to slow or shrink tumors while managing side effects better than traditional high-dose chemotherapy.
This Phase 1 trial tests a chemotherapy drug called paclitaxel in a special “micelle” form in people with advanced solid tumors. It’s mainly designed to check safety and dosing, and it may help shrink tumors in people who don’t have good standard treatment options.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.